Pfizer Creates First COVID-19 Drug: How It Works
Pfizer has announced Phase 1 trials of an experimental new oral antiviral drug for the treatment of SARS-CoV-2. Tests taking place in the USA. This is stated on website.
The oral antiviral drug PF-07321332, a SARS-CoV2-3CL protease inhibitor, has shown potent antiviral activity against SARS-CoV-2 as well as against other coronaviruses, suggesting it could be used in the treatment of COVID-19, as well as potential use to eliminate future coronavirus threats.
“Fighting the COVID-19 pandemic requires both vaccine prevention and targeted treatment for those who have contracted the virus. Given the way SARS-CoV-2 mutates and the ongoing global impact of COVID-19, it seems likely that it will be critical to have access to therapeutic options both now and in the aftermath of the pandemic, said Mikael Dolsten, M.D., Chief Scientist and Pfizer President of International Research, Development & Medicine.
“We developed PF-07321332 as a potential oral therapy that could be prescribed at the first sign of infection without hospitalizing patients. At the same time, Pfizer's intravenous antiviral agent is a potentially new treatment option for hospitalized patients. Together, they can create a holistic treatment paradigm that complements vaccination when illness still occurs, ”Dolsten added.
Protease inhibitors bind to a viral enzyme (called a protease), preventing the virus from replicating in the cell. Protease inhibitors have been effective in treating other viral pathogens such as HIV and hepatitis C virus, either alone or in combination with other antiviral drugs.
Phase 1 is a randomized, placebo-controlled, single dose and multiple dose escalation study in healthy adults evaluating the safety, tolerability and pharmacokinetics of PF-07321332.
You may be interested in: top New York news, stories of our immigrants and helpful tips about life in the Big Apple - read it all on ForumDaily New York.
The start of this study is supported by preclinical studies that have demonstrated the antiviral activity of this potential first-in-class anti-SARS-CoV-2 therapeutic designed specifically to suppress the replication of the SARS-CoV-2 virus.
The structure of PF-07321332, along with preclinical data, will be unveiled at the American Chemical Society's Spring COVID-19 meeting on April 6.
Pfizer is also studying the intravenous PF-07304814 investigational protease inhibitor PF-1, which is currently in phase 19b multi-dose trials involving hospitalized participants in COVID-XNUMX clinical trials.
Read also on ForumDaily:
stdClass Object ([term_id] => 5356 [name] => medicine [taxonomy] => post_tag [slug] => lekarstvo)medicine
stdClass Object ([term_id] => 27233 [name] => World [taxonomy] => category [slug] => mir)World
stdClass Object ([term_id] => 28347 [name] => Special projects [taxonomy] => category [slug] => specproekty)Special Projects
stdClass Object ([term_id] => 28353 [name] => READ ABOUT CORONAVIRUS [taxonomy] => special [slug] => kitajskij-koronavirus)
stdClass Object ([term_id] => 28455 [name] => COVID-19 [taxonomy] => post_tag [slug] => covid-19)COVID-19
Do you want more important and interesting news about life in the USA and immigration to America? Subscribe to our page in Facebook. Choose the "Display Priority" option and read us first. Also, don't forget to subscribe to our РєР ° РЅР ° Р »РІ Telegram - there are many interesting things. And join thousands of readers ForumDaily Woman и ForumDaily New York - there you will find a lot of interesting and positive information.